213 related articles for article (PubMed ID: 16844453)
1. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
[TBL] [Abstract][Full Text] [Related]
2. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
6. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
7. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
[TBL] [Abstract][Full Text] [Related]
8. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
9. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
Gaudet M; Vigneault É; Foster W; Meyer F; Martin AG
Radiother Oncol; 2016 Jan; 118(1):141-7. PubMed ID: 26702991
[TBL] [Abstract][Full Text] [Related]
10. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
11. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
Stone NN; Stock RG
J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
[TBL] [Abstract][Full Text] [Related]
12. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
14. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
Gleave M; Qian J; Andreou C; Pommerville P; Chin J; Casey R; Steinhoff G; Fleshner N; Bostwick D; Thomas L; Rittmaster R
Prostate; 2006 Nov; 66(15):1674-85. PubMed ID: 16927304
[TBL] [Abstract][Full Text] [Related]
15. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
16. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
19. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
20. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
